The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling The Peaks

(Biotech stocks hitting 52-week highs on June 4)

• Adverum Biotechnologies Inc ADVM
• Array Biopharma Inc ARRY
• Arrowhead Pharmaceuticals Inc ARWR
• Insulet Corporation PODD
• Mirati Therapeutics Inc MRTX(reacted to analyst action)
• Misonix, Inc. MSON
• Repligen Corporation RGEN
• Uniqure NV QURE
• Zoetis Inc ZTS

Down In The Dumps

(Biotech stocks hitting 52-week lows on June 4)

• Autolus Therapeutics Ltd – ADR AUTL
• Cellectar Biosciences Inc CLRB
• Cidara Therapeutics Inc CDTX
• Collegium Pharmaceutical Inc COLL
• Invivo Therapeutics Holdings Corp NVIV
• Neurometrix Inc NURO
• Neuronetics Inc STIM
• Orgenesis Inc ORGS
• Psychemedics Corp. PMD
• Teva Pharmaceutical Industries Ltd TEVA
• Trinity Biotech plc TRIB

Stock In Focus

Eli Lilly's Migraine Drug Notches Another FDA Approval

Eli Lilly And Co LLY said the FDA has approved its Emgality injection, 300mg, administered subcutaneously for the treatment of episodic cluster headache in adults. Emgality is a calcitonin gene-related peptide antibody approved by the FDA earlier for the preventive treatment of migraine in adults.

Rewalk's Robotic Stroke Therapy System Gets FDA Nod

Rewalk Robotics Ltd RWLK, which makes robotic medical devices for individuals with lower limb disabilities, said the FDA has approved its ReStore soft exo-suit system for sale to rehabilitation centers across the U.S.

The stock jumped 166.57 percent to $8.85 in pre-market trading.

On The Radar

Clinical Trial Readouts

Roche and AbbVie Inc ABBV will present Phase 3 data for Venclexta plus Gazyva in chronic lympocytic leukemia at the ASCO 2019 annual meeting.

AnaptysBio Inc ANAB is due to present Phase 2a data for ANB020 in severe adult eosinophilic asthma at the European Society for Pediatric Gastroenterology, Hepatology and Nutrition 2019 annual meeting.

Related Links:

The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

How Does Mirati's Lung Cancer Candidate Stack Up Against Amgen's?